On Monday, Madrigal Pharmaceuticals stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 83, up from 63 the day before.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best stocks typically have an RS Rating of at least 80 as they begin their biggest price moves.
Hone Your Stock=Picking Skills By Focing On These Factors
Is Madrigal Pharmaceuticals Stock A Buy?
Madrigal Pharmaceuticals stock has risen more than 5% past a 245.31 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The biotech company showed 0% EPS growth in its most recent report, while sales growth came in at 0%.
Madrigal Pharmaceuticals stock holds the No. 235 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
